Replies to post #108352 on Biotech Values

[DewDiligence]

PFE, Takeda ink Japanese co-promotion for Enbrel, Tofacitinib (PFE’s JAK inhibitor f/k/a tasocitinib):

http://finance.yahoo.com/news/New-CoPromotion-Agreements-bw-265312336.html?x=0&.v=1

Financial terms were not disclosed.

[DewDiligence]

PFE’s Tofacitinib hits primary endpoint in ORAL-Sync Phase-3 trial in RA:

http://finance.yahoo.com/news/Pfizer-Announces-Primary-bw-502052473.html?x=0&.v=1

ORAL-Sync, the second phase-3 trial of Tofacitinib in RA, tested DMARD ± Tofacitinib in the second-line setting. The first phase-3 trial, ORAL-Solo, tested Tofacitinib as monotherapy in the second-line setting and hit its primary endpoint in Nov 2010 (#msg-56398000).

Tofacitinib is shaping up to be the most consequential drug in PFE’s pipeline.